0 results found with selected filters. Please refine the filters. Redirecting to initial search..
Table "column sort" updates the order of the bars in the chart.
downloaded on: 2025/02/17 09:21:32
Strain |
Phenotype |
Conditions |
Study |
Experiment Name |
Sex |
Age |
# of Animals |
Value |
Units |
SEM |
SD |
Method |
Method Duration |
Post Insult Time Value |
Post Insult Time Unit |
Method Notes |
Clinical Measurement Notes |
Record ID |
Study ID |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
111 days-125 days |
18 |
2267.0 |
cells/ul |
74.25 |
315.0 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2 |
111093 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
91 days-105 days |
21 |
1215.0 |
cells/ul |
87.07 |
399.0 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 +Ta1 |
111094 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (between 44 and 4 days) then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) and thymosin alpha-1 (200 ug/kg) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
111 days-125 days |
21 |
3664.0 |
cells/ul |
56.74 |
260.0 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU +IL-2+ Ta1 |
111095 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) and interleukin-2 (75000 U/d) (for 4 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
91 days-105 days |
18 |
987.0 |
cells/ul |
23.81 |
101.0 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU + IL2 |
111092 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
111 days-125 days |
18 |
641.0 |
cells/ul |
161.46 |
685.0 |
fluorescence-activated cell sorting method |
0.0 |
48 |
days |
two treatments |
fluorouracil 5-FU |
111091 |
3196 |
BDIX/OrlCrl |
blood CD25 cell count |
DHD/K12/TRb cells (9 X 10E6) (for 0.1 hours) and splenectomy then 5-fluorouracil (100 mg/kg) (for 7 days) |
Silecchia G, etal., Cancer Immunol Immunother. 1999 Jul;48(4):172-8. doi: 10.1007/s002620050562. |
CD25-positive T cell quantity |
male |
91 days-105 days |
18 |
588.0 |
cells/ul |
49.73 |
211.0 |
fluorescence-activated cell sorting method |
0.0 |
28 |
days |
one treatment |
fluorouracil 5-FU |
111090 |
3196 |
|